Do generic drugs have to run clinical trials like the brand-name drug?
In most countries, generic drugs do not need new, full clinical trials to prove they work the way the original (brand-name) drug does. Instead, regulators typically require evidence that the generic is bioequivalent to the brand—meaning it delivers the active ingredient into the body at a similar rate and extent.
That bioequivalence evidence usually comes from studies in humans (commonly called bioequivalence or pharmacokinetic studies), but these are generally not the same type of efficacy/safety clinical trials used to establish the original drug’s effects.
What evidence do generic manufacturers usually submit instead of new efficacy trials?
Generic approval commonly relies on a combination of:
- Formulation and manufacturing evidence showing the generic has the same active ingredient and meets quality standards.
- Bioequivalence testing showing similar absorption compared with the reference product.
- Stability and other chemistry/quality data to demonstrate the product is properly manufactured and will maintain quality over its shelf life.
Because the active ingredient and its clinical performance have already been established for the reference drug, regulators often consider bioequivalence studies sufficient for most “typical” generic products.
When might a “generic” need additional clinical testing?
Some situations can require more than standard bioequivalence studies, depending on the product and the regulator’s rules. Common examples include:
- Complex drug formulations (such as certain extended-release products) where demonstrating bioequivalence can be harder.
- Narrow therapeutic index drugs, where small differences in exposure can matter more and may require tighter evidence.
- Products where bioequivalence cannot be adequately demonstrated with the usual approach, prompting additional studies or special requirements.
In those cases, manufacturers may need more extensive bridging studies or other data, even if a full new efficacy trial is still often not required.
Do biosimilars work the same way as generics?
No. Biosimilars are different from small-molecule generics. Even when biosimilars do not repeat all brand-name clinical trials, they usually require a more involved development package, often including additional clinical data beyond bioequivalence alone because biologics are more complex and not identical to the reference product.
What about regulatory systems and “approved” labeling?
Whether a generic requires clinical trials can also depend on the regulatory pathway used (for example, whether it is a traditional generic application versus a specific abbreviated pathway). Across most systems, the goal is the same: show the generic is equivalent to the approved reference product, usually without repeating the entire efficacy trial process.
If you tell me which country (FDA/US, EMA/EU, UK, Canada, etc.) and whether you mean a small-molecule generic or a biosimilar, I can map the exact requirements more precisely.